Dani Castillo
@DaniCastilloMD
Followers
51
Following
72
Media
8
Statuses
50
Medical Oncologist/ Researcher @COH
Duarte, CA
Joined June 2024
Abiraterone 250mg vs. 1000mg? Multiple studies continue to show similar efficacy and ⬇️ cost (though through @costplusdrugs @mcuban, cost has gone ⬇️ significantly…), should the lower dose be the SoC in CRPC and higher dose be used as a back-up? #OncTwitter #gusm @JCOGO_ASCO
13
91
279
PARP Inhibitors in Gastric Cancer: Unlocking Precision Oncology https://t.co/kdwhy6X7Lb
#oncologist @DanengLi
academic.oup.com
Abstract. Gastric cancer (GC) demonstrates frequent alterations in homologous recombination repair (HRR) genes, and preclinical studies have demonstrated a
0
0
5
Cachexia is a common complication of cancer and is associated with an increased risk of mortality. The level of Growth Differentiation Factor 15 (GDF-15), a circulating cytokine, is elevated in patients with cancer cachexia. This suggests that GDF-15 could be a valuable biomarker
Thanks for highlighting @DrHendifar & our @CSCancerCenter team’s study in @JCOOA_ASCO comparing serum lvls of GDF-15 in #PDAC vs healthy controls. Relevant as GDF-15 is a potential therapeutic target to address #PDAC cachexia @DrR_DUNNE: https://t.co/fHyiZbVVEE
@OncoAlert
0
1
1
Last night was an evening to #celebrate each other! Congrats 🍾 to @aparna1024 @KlempnerSam as new #CRC and #UGI section heads @MGHCancerCenter as well as @NataliyaUboha the new #AD for #clinicalresearch @UWCarbone 👏 👏! @rutikamehtaMD and Dr. R Ness!
2
2
33
Esophageal, GEJ and Stomach Cancer Stage IV Support Meeting
us02web.zoom.us
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom...
0
0
1
Dr. Gagandeep Brar @gagan_brar24 @cityofhope discusses new findings in #GI cancers from the @ASCO meeting , translating evidence from KEYNOTE-016, ATOMIC, and MATTERHORN into practice #IOSymposium2025 @ANCO_News @MOASC_Office
0
3
8
Incredibly proud of @gagan_brar24, one of the shining stars of our GI program at @cityofhope. She delivered a spectacular talk at the joint @MOASC_Office @ANCO_News #Immuno #oncology meeting, led by @OmidHamidMD & @DrBetofMDPhD! @DrRaviSalgia @mgfakih @DanengLi @DrMvandenBrink
0
4
20
Excited to share our recent publication! It's been a pleasure working with our amazing residents during their hem/onc rotations.# frontier in Oncology #ctDNA @DanengLi @gagan_brar24
0
2
15
Thank you very much Doctor @montypal. This wouldn’t be possible without your incredible support and mentorship! 💙
Beautiful work (as usual) @SalvadorjcMD! Colleagues, Salvador will be applying to #urology residency programs this year. He has worked closely with our @cityofhope team, including myself, @WesleyYipMD, @AbhiTrip87 et al. I can think of few trainees I have worked with in the past
2
3
30
What a treat to chat with Dr. Elkrief @chumontreal about the impact of the #microbiome on #cancer #outcomes! A dear friend & collaborator, we haven't had time in a while to chat for some time about updates in the field. Go to the link below & check out Table 3 - one of the most
🎙 @montypal of @cityofhope and Dr. Arielle Elkrief of @chumontreal @CRCHUM discuss the emerging phenomenon of the gut microbiome and its relationship to cancer immunotherapy on the latest episode of the #ASCODailyNews Podcast: https://t.co/v73Y9uWNTB
4
10
31
Microbiota driven gut TME changes, responder vs. non responder.# microbiome
2
3
12
Powerful-Pro app in the clinic, new innovation from Dr. Jiang
Just a quick note: the free version gives full access to all 850 CTCAE v6 and 808 v5 AEs. You can look up anything, anytime — even offline. Free is powerful- Pro mode just makes day-to-day use easier: unlimited favorites (vs. 5), unlimited patient cases (vs. 1), and case sharing.
0
0
1
So excited for the future of @ASCO and honored to play a small role in it with this impressive group of people on the Nominating Committee and the amazing ASCO staff! @DanaFarber
Wonderful meeting @ASCO HQ - such an honor to serve on the #NominatingCommittee with a stellar group of people, great discussions and humbled to help find the next slate of leaders for our society! @montypal @SuzanneColeMD @ErikaHamilton9 @DrRanaMcKay @lynn_schuchter @ASCOPres
2
7
72
On the newest episode of On the Edge of Breakthrough: Voices of Cancer Research, @montypal and Dr. Kelly Mahuron, a surgical oncologist at City of Hope, unpack how tumor-infiltrating lymphocyte (TIL) therapy is evolving and more. Watch and subscribe: https://t.co/neFmxtTkMf
3
10
16
Had a wonderful coffee time with Dr. Michael Vieth, Chair of General Pathology at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and director of the Institute of Pathology at Klinikum Bayreuth in Germany .# gastric cancer #coh #rifatmannan# early detection of gastric
1
2
9
The appearance of large language models caused a drastic shift in the vocabulary of academic writing, according to an analysis in @ScienceAdvances of more than 15 million biomedical abstracts published from 2010 to 2024. https://t.co/SKB0pzHCJn
14
45
143
Very nice panel discussion on metastatic #colorectalcancer @Drs. Raghav @skopetz @KristenCiombor with @GIcancerDoc. @_MDEducation #cancer @MDAndersonNews @VUMCDiscoveries @EileenMOReilly
0
3
22
Hear as @elizabeth_budde of @cityofhope shares the promising results of a Phase II study evaluating mosunetuzumab plus polatuzumab vedotin in pts with R/R #MantleCellLymphoma & high-risk features. Click here: 🎥 https://t.co/yv0s5nGxRy
#LYMsm #18ICML #CTSM #TrialUpdate
vjhemonc.com
Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, discusses the promising results of a Phase II study evaluating the combination of mosunetuzumab and polatuzumab vedotin in patients with relapsed...
1
2
5